ReNeuron presented new data highlighting the advantages of its novel type of iPSCs including data
from the Company’s collaboration with University College London.
The presentation entitled Conditionally Immortalised iPSCs: A New Approach to Off-the-Shelf Allogeneic iPSC-Derived Cell Therapies can be viewed by clicking here.